Search

Author/Creator Babacan, Nalan Akgul

3. How long should we continue crizotinib in ALK translocation-positive inflammatory myofibroblastic tumors? Long-term complete response with crizotinib and review of the literature. (June 2020)

Authors:
Alan, Ozkan; Kuzhan, Okan; Koca, Sinan; Telli, Tugba Akin; Basoglu, Tugba; Ercelep, Ozlem; Filinte, Deniz; Sengul, Yildiz; Arikan, Huseyin; Kaya, Serap; Babacan, Nalan Akgul; Dane, Faysal; Yumuk, Perran Fulden
Journal:
Journal of oncology pharmacy practice
Issue:
Volume 26:Number 4(2020)
Page Start:
1011
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Prognostic factors in progressive high-grade glial tumors treated with systemic approach: A single center experience. (March 2021)

Authors:
Alan, Ozkan; Telli, Tugba Akin; Tuylu, Tugba Basoglu; Arikan, Rukiye; Demircan, Nazım Can; Ercelep, Ozlem; Kaya, Serap; Babacan, Nalan Akgul; Atasoy, Beste M; Bozkurt, Suheyla; Bayri, Yasar; Gul, Dilek; Ekinci, Gazanfer; Ziyal, Ibrahim; Dane, Faysal; Yumuk, P Fulden
Journal:
Journal of oncology pharmacy practice
Issue:
Volume 27:Number 2(2021)
Page Start:
329
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗